Ropinirole therapy for Parkinson's disease.

  title={Ropinirole therapy for Parkinson's disease.},
  author={Rajesh Pahwa and Kelly E. Lyons and Robert A. Hauser},
  journal={Expert review of neurotherapeutics},
  volume={4 4},
Ropinirole (Requip, GlaxoSmithKline) is a novel nonergoline dopamine D2 agonist indicated for the treatment of early and advanced Parkinson's disease. It is mainly metabolized by the liver and its elimination half-life is approximately 5.8 h. When used as monotherapy in early Parkinson's disease, ropinirole improves signs and symptoms of the disorder. When used as an adjunct to levodopa in advanced Parkinson's disease patients with motor fluctuations, ropinirole reduces off time and allows a… CONTINUE READING